Compare AGNCM & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
AGNC Investment Corp. Depositary Shares rep 6.875% Series D Fixed-to-Floating Cumulative Redeemable Preferred Stock
Current Price
Current Price
| Metric | AGNCM | INM |
|---|---|---|
| Founded | 2008 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 7.1M |
| IPO Year | 2008 | 2020 |
| Metric | AGNCM | INM |
|---|---|---|
| Price | $25.25 | $1.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.1K | ★ 59.7K |
| Earning Date | 01-26-2026 | 05-12-2026 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | 58.06 | ★ 62.68 |
| EPS | ★ 0.37 | N/A |
| Revenue | N/A | ★ $4,942,633.00 |
| Revenue This Year | $13.57 | N/A |
| Revenue Next Year | $63.17 | N/A |
| P/E Ratio | $68.00 | ★ N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $23.63 | $0.58 |
| 52 Week High | $25.54 | $2.50 |
| Indicator | AGNCM | INM |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | 50.74 |
| Support Level | $25.07 | $1.35 |
| Resistance Level | $25.54 | $1.40 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 42.58 | 54.88 |
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage, or real estate markets.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.